This study was designed to investigate whether Resveratrol (Res) could be a prophylactic factor in the prevention of I/R injury and to shed light on its underlying mechanism. Primary culture of neonatal rat cardiomyocytes were randomly distributed into three groups: the normal group (cultured cardiomyocytes were in normal conditions), the I/R group (cultured cardiomyocytes were subjected to 2 h simulated ischemia followed by 4 h reperfusion), and the Res+I/R group (100 µmol/L Res was administered before cardiomyocytes were subjected to 2 h simulated ischemia followed by 4 h reperfusion). To test the extent of cardiomyocyte injury, several indices were detected including cell viability, LDH activity, Na+-K+-ATPase and Ca2+-ATPase activity. To test apoptotic cell death, caspase-3 activity and the expression of Bcl-2/Bax were detected. To explore the underlying mechanism, several inhibitors, intracellular calcium, SOD activity and MDA content were used to identify some key molecules involved. Res increased cell viability, Na+-K+-ATPase and Ca2+-ATPase activity, Bcl-2 expression, and SOD level. While LDH activity, capase-3 activity, Bax expression, intracellular calcium and MDA content were decreased by Res. And the effect of Res was blocked completely by either L-NAME (an eNOS inhibitor) or MB (a cGMP inhibitor), and partly by either DS (a PKC inhibitor) or Glybenclamide (a KATP inhibitor). Our results suggest that Res attenuates I/R injury in cardiomyocytes by preventing cell apoptosis, decreasing LDH release and increasing ATPase activity. NO, cGMP, PKC and KATP may play an important role in the protective role of Res. Moreover, Res enhances the capacity of anti-oxygen free radical and alleviates intracellular calcium overload in cardiomyocytes.
5 July 2024 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
BACKGROUND We report a case of a giant (55×35×27 cm, 26 kg) retroperitoneal liposarcoma (RPLS) to provide surgical insights for managing such complex tumors. Due to the potential space in the retroperitoneal cavity, primary retroperitoneal liposarcoma can grow to very large sizes without causing typical symptoms, frequently encasing critical vessels and organs and making resection highly challenging. Most chemotherapy drugs have limited effectiveness against RPLS, while radiotherapy dosages are significantly constrained by toxicity concerns. These limitations underscore why complete surgical resection (R0) continues to be the cornerstone of RPLS treatment and the single most important prognostic factor. While R0 resection remains the primary treatment, innovative approaches are needed to improve outcomes. CASE REPORT A 59-year-old man came for medical treatment due to the continuous growth of an abdominal mass for 2 years. Imaging revealed tumor encasement of the left renal vessels and descending colon, with compression of the aorta and inferior vena cava. Following multidisciplinary evaluation, vascular-oriented resection (VOR) combined with total retroperitoneal lipectomy (TRL) was performed, achieving complete tumor removal along with the involved left kidney and partial colon. Pathology confirmed dedifferentiated liposarcoma (MDM2/CDK4+, Ki-67 10-30%). Postoperatively, the patient showed significant improvement, with resolved lower-limb edema and dyspnea. CONCLUSIONS This case demonstrates the feasibility of VOR combined with TRL for giant retroperitoneal liposarcoma, highlighting the importance of preoperative 3D vascular reconstruction and multidisciplinary collaboration. Although surgical techniques have advanced, the 5-year recurrence rate remains unacceptably high at nearly 50%, highlighting the urgent need to explore more effective adjuvant therapies.
Hepatocellular carcinoma (HCC) accounts for third most cancer death globally, and its prognosis continues to be poor even with many novel therapeutic approaches emerging. The advent of immunotherapy seems to offer new hope, but low response rates are an unresolved problem. To gain further knoeledge of the effect of immune-related genes in HCC, we examined the connection between immune-related genes and the immune microenvironment in HCC through the HCC transcriptome dataset. The study also aimed to construct and experimentally validate user-friendly molecular subtypes mediated by immune-related genes in HCC. The immune cell infiltration patterns differs in HCC adjacent non-disease tissues and cancerous tissues. Patients with HCC could be classified into 2 subtypes: subtype A and subtype B. Specifically, subtype A shows characteristics of a hot tumor, in which the infiltration of cells exhibiting antigens and the expression of other crucial factors associated with immune function are higher than in a cold tumor. In addition, we identified Hub genes for the different subtypes and constructed a prognostic prediction model based on six genes (KLRB1, KLF2, S100A9, MSC, ANXA5, and IMPDH1). Further experimental analysis of HCC samples exhibited that the expression levels of KLF2 and ANXA5 were associated with immune cell infiltration and expression of PD-L1 in cancer tissues. Our work suggests that the expression of immune-related genes has crucial effect on the tumor microenvironment and prognosis of HCC patients and may be associated with immunotherapeutic response, which provides new clues for the widespread and effective application of immunotherapy in HCC.
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by a poor prognosis. Mitochondrial dysfunction, including alterations in metabolism, dynamics, and DNA, is increasingly recognized as a critical factor in the initiation and progression of pancreatic cancer. This study aimed to systematically investigate the role of mitochondrial dysfunction in PDAC to identify mitochondria-related genes (MitoRGs) of prognostic significance, explore associated molecular subtypes, and examine their effects on the tumor immune microenvironment. Methods: We integrated transcriptomic data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to identify a set of MitoRGs with significant prognostic value for PDAC. Their expression was further validated in PDAC cells and using single-cell RNA-sequencing data. Unsupervised clustering was employed to classify PDAC patients into distinct subtypes based on MitoRG expression patterns. A robust prognostic model was subsequently constructed using least absolute shrinkage and selection operator-Cox regression analysis. The predictive accuracy of the model for 1-, 3-, and 5-year overall survival (OS) was assessed. The immune cell infiltration and genomic features of the risk groups defined by the model were also analyzed. Finally, a clinically applicable nomogram was developed to facilitate prognostic prediction. Results: Based on MitoRG expression, PDAC patients were classified into two distinct subtypes (clusters A and B). Patients in cluster A exhibited significantly better OS than those in cluster B. A prognostic model based on a seven-MitoRG signature was established, which demonstrated high predictive accuracy. The high-risk group, as defined by the model, was characterized by an immunosuppressive tumor microenvironment, featuring reduced cytotoxic T-cell activity and increased stromal components. This group also showed significant enrichment of driver mutations such as KRAS and TP53. Conclusions: This study established a significant link between mitochondrial dysfunction and PDAC molecular subtypes, immune microenvironment remodeling, and clinical prognosis. The developed seven-MitoRG signature and nomogram could serve as reliable prognostic tools. These findings provide insights into the role of mitochondria in the pathogenesis of PDAC and offer potential targets for developing personalized therapeutic strategies.